Valuation: Ardelyx, Inc.

Market Cap 1B 861M 804M 738M 1.39B 95.99B 1.41B 9.49B 3.72B 48.14B 3.77B 3.69B 159B P/E 2026 *
-22.6x
P/E 2027 * 17.4x
Enterprise Value 1B 861M 804M 738M 1.39B 95.99B 1.41B 9.49B 3.72B 48.14B 3.77B 3.69B 159B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.61x
Free-Float
95.8%
Yield 2026 *
-
Yield 2027 * -
1 day-2.85%
1 week+0.13%
Current month-20.91%
1 month-23.08%
3 months-37.56%
6 months-31.68%
Current year-32.85%
1 week 3.86
Extreme 3.86
4.09
1 month 3.86
Extreme 3.86
5.21
Current year 3.86
Extreme 3.86
8.4
1 year 3.86
Extreme 3.86
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 2009-02-28
Director of Finance/CFO 55 2025-11-03
Chief Tech/Sci/R&D Officer 50 2026-03-31
Director TitleAgeSince
Director/Board Member 61 2009-02-28
Chairman 60 2014-02-28
Director/Board Member 59 2014-02-28
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Fiscal year

Chief Executive Officer

83,336 0.0337%
2/24/26 Fiscal year

Chief Executive Officer

83,332 0.0343%
2/20/26 Sell

Chief Technology Officer

3,179 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
-2.85%+0.13%-34.64%+9.36% 1B
-1.90%+3.12%+81.70%+110.88% 72.21B
+0.48%+16.86%+56.53%+93.29% 63.98B
-2.98%+0.28%-2.13%+475.86% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-4.42%+17.10%-3.08%-8.21% 28.42B
-0.51%+5.28%+38.13%-14.55% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-0.33%+6.54%+42.42%+152.32% 13.48B
Average -0.70%+5.30%+51.00%+181.28% 28.69B
Weighted average by Cap. -0.74%+6.68%+59.65%+160.75%

Financials

2026 *2027 *
Net sales 489M 419M 392M 359M 675M 46.72B 687M 4.62B 1.81B 23.43B 1.84B 1.8B 77.47B 624M 535M 500M 458M 862M 59.63B 876M 5.9B 2.31B 29.91B 2.34B 2.29B 98.89B
Net income -44.5M -38.17M -35.64M -32.7M -61.49M -4.25B -62.51M -421M -165M -2.13B -167M -163M -7.05B 62.15M 53.32M 49.78M 45.68M 85.89M 5.94B 87.31M 587M 230M 2.98B 233M 228M 9.85B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
26-08-20 US$3.915 -2.85% 656,208
26-08-19 US$4.030 +2.81% 3,050,143
26-08-18 US$3.920 -3.45% 4,041,483
26-08-17 US$4.060 0.00% 3,667,535
26-08-14 US$4.060 +3.84% 3,978,332
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.030USD
Average target price
12.90USD
Spread / Average Target
+220.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock